



Chinese Journal of Tuberculosis and Respiratory Diseases recommended the use of Pirfenidone as an anti-fibrosis therapy for COVID-19 patients in China

November 2, 2020 — 《中华结核和呼吸杂志》 The Chinese Journal of Tuberculosis and Respiratory Diseases recently published an article called “Expert recommendations for the diagnosis and treatment of interstitial lung disease caused by coronavirus pneumonia” on October 12, 2020 recommending the use of Pirfenidone as an anti-fibrosis therapy for COVID-19 patients in China.

<http://rs.yiigle.com/CN112147202010/1247738.htm>

The Chinese Journal of Tuberculosis and Respiratory Diseases is professional academic journal under Chinese Medical Association and China Association for Science and Technology, one of the leading authoritative journal for Respiratory Diseases in China.

As stated in our previous news release on March 10, 2020 and March 24, 2020, our consolidated subsidiary Beijing Continent Pharmaceutical Co., Ltd is supporting 2 medical institutions for clinical studies to evaluate the efficacy and safety of Pirfenidone for COVID-19 infections and we will continue to work with medical institutions closely to provide support for the fight against this global pandemic.